Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

7 evidence topics · 7 sources

Participants aged 65 years and older in the phase 3 trials
Trial and armAge, years, minimum and maximumAge 65 years or older, n (%)
COMP005, COMP360 25 mg (N=171)“19, 77”“15 (8.8)”
COMP005, placebo (N=87)“22, 72”“11 (12.6)”
COMP006, COMP360 25 mg (N=296)“18, 79”“29 (9.8)”
COMP006, COMP360 10 mg (N=142)“19, 73”“9 (6.3)”
COMP006, COMP360 1 mg (N=143)“20, 75”“13 (9.1)”